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Summary 
Our earlier reports demonstrated that Cynomolgus macaques vaccinated with either inactivated 
partially purified simian immunodeficiency virus (SIV),  fixed SIV-infected C8166  (a human T 
lymphoblastoid cell line) cells, or fixed uninfected C8166 cells can be protected against a challenge 
infection with the 32H isolate of SIVmac 251  (grown in C8166)  (Stott, E. J.,  W.  L. Chan, 
K. H. G. Mills, M. Page, F. Taffs, M. Cranage, P. Greenway, and P. Kitchin. 1990. Lancet. 336:1538; 
Stott, E. J., P. A. Kitchin, M.  Page, B. Flanagan, L. F. Taffs, W.  L. Chan, K. H.  G. Mills, 
P. Silvera, and A. Rodgers. 1991. Nature[Lond.].  353:393).  Protection is correlated with the levels 
of antibody response  to cellular antigens in the human cells from which the virus immunogen 
was grown. However, the mechanism of protection is unclear.  We report here the analysis of 
sera from these protected monkeys and demonstrate that there is positive correlation of protection 
with antibody response to the HLA class I molecule. 
M 
acaques infected with the simian immunodeficiency virus 
. (SIV) develop a disease similar to that produced by HIV 
in humans. This simian model is therefore widely used in 
Europe and the United States for the development of vac- 
cines against AIDS (1-3).  Recently, we demonstrated that 
Cynomolgus macaques vaccinated with either inactivated par- 
tially purified SIV, fixed SIV-infected C8166 cells, or even fixed 
uninfected C8166  cells can be protected against a challenge 
infection with the 32H isolate of  SIVmac 251 grown in C8166 
cells (4-6).  Protection is correlated with the levels of anti- 
body response to cellular antigens in the human cells (5, 7-10). 
In the present study, we demonstrate that protection is directly 
correlated with antibody response to the HLA class I mole- 
cules. These results suggest that antibodies against HLA class 
I molecule and/or other yet undetected antigen(s) may be 
useful in immunotherapy against HIV infection. 
Materials and Methods 
Animals.  Cynomolgus monkeys  (Macacafascicularis) were main- 
tained in accordance with Guidelines for the Housing and Care 
of Laboratory Animals Used in Scientific  Procedures (1989; Home 
Office, UK). They were vaccinated  as described previously (4, 5). 
Monkeys I179-182 were injected subcutaneously four times with 
500 #g formalin-fixed SIVmac 251 (32H isolate; 11/88 pool)  + 
SAF-1 adjuvant; monkeys  J134-137 were injected subcutaneously 
three times with 500 #g formalin-fixed  SIVmac 251  + RIBI adju- 
vant; monkeys  J138-141 were injected subcutaneously four times 
with 100 #g formalin-fix~l  SIVmac  251 + RIBI; monkeys  I217-220 
and J68-71 were injected subcutaneously with two doses, respec- 
tively, of 2  x  106 SIVmac 251-infected C8166 cells fixed with 
glutaraldehyde +  Quil-A adjuvant; and monkeys  J72-75 were in- 
jected subcutaneously  with two doses of 2 x  106 C8166 cells fixed 
with glutaraldehyde + Quil-A adjuvant. All the animals  were chal- 
lenged  intravenously with  10  50%  monkey  infectious doses 
(MIDs0) SIVmac 32H isolate, 11/88 pool (grown in C8166 cells) 
1 wk after the final boost. Protection was determined using the 
previously described method of PCK for SIVmac proviral DNA 
with gag, pol as primers (11), as well as by virus isolation using 
direct cocultivation of  monkey PBMC with C8166 cells. Virus was 
detected  by the appearance  of  cytopathic  effects  (CPE) and confirmed 
by immunofluorescence  of  virus antigen on infected  cells using stan- 
dard methods. Cultures that did not show CPE were maintained 
for at least 28 d before being discarded as negative. 
Immune Precipitation.  Actively dividing C8166 cells (20-30  x 
106) were labeled for  6  h  with  0.5  mCi  [3SS]methionine in 
methionine-ffee RPMI containing 10% FCS, lysed, and radioim- 
mune precipitated as previously described (12). The washed im- 
mune complexes were reduced and subjected to electrophoresis  in 
a 12.5% acrylamide gel .Gels were treated with Amplify (Amer- 
sham Corp., Arlington Heights, IL), dried, and exposed to Kodak 
X-Omat  KP film at  -70~ 
Flow Cytometry Analysis.  100 ~1 of a suspension of 106 P815 
or P815 cells transfected with human HLA class I molecules B27 
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100/zl of serial fourfold dilutions (1/30-7,680)  of monkey plasma 
(from day of challenge or prebleed as control) containing 0.1% so- 
dium azide for 30 min at 4~  The cells were washed thrice in 
RPMI with 10% FCS and sodium azide before a further 30-rain 
incubation  with 100 #1 of 1:100 of rabbit  antibody to human  Ig 
conjugated  to FITC (Dako Corp.,  Santa Barbara, CA). The ceils 
were washed as before and resuspended in PBS containing 1% form- 
aldehyde. The percentage and peak channel fluorescence were ana- 
lyzed on a FACS  |  Consort 30 (Becton Dickinson & Co., Moun- 
tain View, CA). The end-point titer was taken as the dilution where 
)20%  of the cells were positive. 
ELISA.  The 32H cognate isolate of SIVmac 251 and the HIV-1 
isolate, GB8, were grown in C8166 cells and partially purified by 
gel exclusion chromatography  to minimize loss of envelope glyco- 
protein  (13). Both virus preparations  were inactivated with for- 
malin and dialyzed into  PBS before use. For the ELISA, 50 #1 of 
SIVmac (2 #g/ml) or HIV-1 (16/~g/ml) diluted in 0.1 M carbonate 
buffer, pH 9.6, was added to each well of a 96-well microtiter plate 
(Maxi Sorb; Nunc,  Roskilde, Denmark)  and all subsequent steps 
were carried out as previously described (14). mAbs and rabbit an- 
tibody to human Ig conjugated  to horse radish peroxidase (1:100; 
Dako Corp.) were diluted in PBS containing 0.05% Tween 20 and 
10% heat-inactivated newborn calf serum (HI NCS). Dilutions of 
mAbs (50/~1) used were 1:100 for ascites fluid, 20-50/~g/ml for 
purified Ig, and neat spent tissue culture supernatant.  All washes 
were with PBS containing  0.05% Tween 20. The substrate used 
was  2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic  acid) (Sigma 
Chemical Co., St. Louis, MO) and the OD was measured at 405 
nm.  The  mAbs  used  were  obtained  from  the  AIDS  Directed 
Programme, Medical Research Council,  UK (ADP373, ADP317, 
ADP318, ADP336,  ADP351, ADP356,  ADP359);  the American 
Type Culture Collection,  Rockviile, MD (W6/32, L203, L227, 
L243, OKT3); Professor  J. Lamb, St. Mary's Hospital, London and 
Bristol-Myers Squibb, Seattle, WA (9.3); and OKTll  and nm31 
were kind gifts from Dr. D. Cantreil,  Imperial Cancer Research 
Fund, Lincoln's Inn Field, London, and Prof. A. McMichael, Insti- 
tute for Molecular Medicine, Oxford, respectively. All the mAbs 
used have been checked for activity using flow cytometry (data not 
shown). 
Results and Discussion 
Radioimmune  precipitation  of  [3SS]methionine-labeled 
C8166 cell lysate with  the monkey sera demonstrated  that 
all the sera from protected but not from unprotected monkeys 
recognize two major protein bands  at  12 and 44 kD (Fig. 
1). These bands were precipitated by sera from all the pro- 
tected animals in the vaccine groups studied but not by their 
preirnmune sera. Blocking experiments were carried out with 
[3SS]methionine-labded C8166 ceU lysate by preprecipitation 
with serum from protected monkeys followed by precipita- 
tion with mAb W6/32  (specific for a monomorphic deter- 
minant  on human MHC class I molecule HLA-A, -B, -C). 
Alternatively, the lysate was preprecipitated with rabbit anti- 
/32m (the/3  chain  of HLA  class  I  molecule)  followed by 
precipitation  with  serum from protected monkeys. Results 
shown in Fig. 2 demonstrate that the 12- and the 44-kD bands 
are/32m  and the heavy (o  0  chain of HLA dass I  molecule, 
respectively. 
The  intensity  and mass of the bands  around  the 44-kD 
region precipitated by sera from some protected monkeys (Fig. 
1) suggest that other T cell surface proteins with similar mo- 
lecular masses, such as CD28 (44 kD), CD2 (Tll,  50 kD), 
and actin  (44 kD),  may also be recognized.  However, the 
sera from protected monkeys vaccinated with purified SIVmac 
251 virus do not contain anti-CD2  (Fig.  2 b) or anti-CD28 
antibodies (data not shown). The sera from protected monkeys 
did not precipitate the ol chain  or the 13 chain of the class 
I  molecule  of [3SS]methionine-labeled,  Herpes papio-trans- 
formed monkey B lymphoblastoid cell lines (Fig. 2 c), sug- 
gesting that the anti-human class I antibodies in the sera are 
directed at polymorphic regions of the human HLA class I 
Figure  1.  Sera from protected 
monkeys  contain antibodies specific 
for human HLA class I molecule. 
[3sS]Methionine-labeled  C8166 cell 
lysates were immune precipitated 
with prebleed  (B) and hyperimmune 
(.4) plasma (20/~1) from monkeys 
vaccinated  with inactivated  purified 
SIVmac (I179, I180, 1181, 1182), 
fixed  SIV-infected  C8166 cells  (I217, 
I219, J68, J69, J71), or C8166 cells 
073, J75). With the exception of 
J71, J75, and 1219, all the other 
monkeys were protected against 
SIVmac  251 (grown  in C8166  cells) 
challenge infection (reported  in ref- 
erences 4 and 5). 
1204  Anti-HLA  Class I Antibody and Simian Immunodeficiency  Virus Protection Figure 2.  (a) In lanes 1181  +  W6/32 and anti-Bzm +  1182, the radiolabeled lysate was preprecipitated twice with plasma from 1181 or anti-/~2m 
before subsequent precipitation with mAb W6/32 or I182 plasma, respectively. (b) Similarly, in lane 1181  + OKTII, precipitation with mAb OKTll 
was subsequent to that with 1181 plasma.  Lane 1181 PB denotes preimmune plasma.  (c) [3sS]Methionine-labeled  cell lysates of a H. papio-transformed 
monkey B lymphoblastoid cell line were immune precipitated with 25 #1 prebleed or hyperimmune plasma from protected monkey I181 and 2 #1 (ascites 
fluid) of mAbs W6/32 or L243 (specific for nonpolymorphic determinants of human class II molecule HLA-DR). Similar results were obtained with 
sera from other protected monkeys. 
Table  1.  Detection  of Cellular  Antigens  on SIV and HIV-I  Virions  by ELISA 
OD  reading* 
Antigen 
Antibody  recognized  SIV  HIV- 1 
None  -  0.06  -+  0.007  0.014  _+  0.003 
ADP373  IgG2a  SIV env  gp160  0.344  _+  0.025  ND 
ADP317  IgG3  HIV-1  env  gp160  ND  0.116  _+  0.005 
W6/32  IgG2a  HLA-A,-B,-C  0.333  _+  0.038  0.113  __  0.012 
OKT3  IgG2a  CD3  0.314  _+  0.06  0.323  __  0.008 
L203  IgG1  HLA  class II  0.017  __  0.001  0.012  __  0.004 
L227  IgG1  HLA  class II  0.017  _+  0.001  0.008  +  0.001 
L243  igG2a  HLA  class  II  0.05  _+  0.009  0.058  _  0.01 
nm31  IgG  HLA  class II  0.036  _+  0.004  0.032  _+  0.008 
OKTll  IgG2a  CD2  0.043  _+  0.009  0.027  +_  0.003 
9.3  IgG2a  CD28  0.03  _+  0.002  0.014  _+  0.002 
ADP318  IgG1  CD4  0.014  _+  0.002  0.011  _+  0.006 
ADP336  IgG2a  CD4  0.058  _+  0.006  0.062  __  0.002 
ADP351  IgG2a  CD4  0.025  _+  0.003  0.020  _+  0.008 
ADP356  IgG2b  CD4  0.036  -+  0.002  0.033  _+  0.001 
ADP359  IgG  CD4  0.016  _+  0.001  0.007  +_  0.001 
" Values (mean  _+  1 SEM, n  =  6) that were five times higher than the negative control reading wee considered as positive (in bold type). 
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Flow cytometry analysis of anti-human HLA class I reac- 
tivity by prebleed and hyperimmune plasma (1:30) from a representative 
monkey, I181, using mouse P815 cells transfected with HLA B27. To con- 
trol for nonspecific binding, the same set of plasma was also used to react 
with untransfected P815 cells (data not shown). Similar results were ob- 
tained with sera from other protected monkeys. 
molecule. Flow cytometry analysis also shows that sera from 
protected monkeys recognized a routine cell line (P815) trans- 
fected with human HLA class I B27 (Fig. 3); mean antibody 
titer of protected monkeys was log10 3.1  _+  0.13 (n  =  32), 
and of the unprotected group was 1.86  +  0.09  (n  =  11), 
p  <  0.0005. 
The high levels of anti-human HLA class I antibody in- 
duced in protected monkeys vaccinated with purified SIVmac 
251 virus (grown in C8166 cells) suggest that the purified 
virus preparation may contain HLA class I antigen. The ELISA 
results (Table 1) confirm that the partially purified SIVmac 
251 virus preparation used for immunization, and an HIV 
vaccine preparation (GB8), contain an HLA class I molecule 
and, additionally, CD3, a T cell antigen-forming part of the 
TCR complex, but little or no detectable CD4,  CD2,  or 
CD28 antigens. However, sera from protected monkeys were 
not able to precipitate any bands depicting the CD3 %  & 
~, ~', and ~/chains (26,  20,  and 16 kD) (Fig.  1), indicating 
that CD3 was poorly immunogenic in these monkeys and 
that the level of anti-CD3, if present, is below the limit of 
our assay system. In contrast to a previous report (15), we 
failed to detect class II antigens in our SIV preparation. This 
may be due to the different procedures used in purifying the 
viruses. 
Our results demonstrate a direct correlation between anti- 
body response to human HLA class I antigen and protection 
of monkeys from SIVmac 251 (grown in C8166 cells) infec- 
tion. The mechanism of the possible protection by this anti- 
body is at present unclear. It may be that the antibody reacts 
with the human class I antigens in the virus envelope (Table 
1) and thereby blocks the interaction of gp120 with the CD4 
determinant on the target cells by steric hindrance. How- 
ever, the anti-human HLA class I antibody does not recog- 
nize monkey HLA class I antigen (Fig.  2 c). This may ex- 
plain the observation that the vaccinated monkeys were infected 
on subsequent challenge with SIV grown in monkey cells, 
even though they had previously been protected against SIV 
grown in C8166 cells (8-10, and our unpublished data). Al- 
though sera from these monkeys also contain high levels of 
specific anti-SIV antibodies (7, 8, 10, 16, 17, and our unpub- 
lished data), the lack of protection suggests that neutralizing 
antibodies may not be a major protective mechanism in the 
present system. However, it does not rule out the possibility 
for selection of genetic variants in the virus grown in monkey 
cells that are critically divergent from the vaccine virus used, 
which was grown in C8166 cells. Such changes could account 
for the possible breakdown in immune surveillance by the 
existing SIV-specific neutralizing antibodies in the monkeys. 
This is evident when recombinant env is used as vaccine and 
the specific neutralizing antibody induced could only pro- 
tect monkeys against a homologous challenge infection with 
cloned SIV (18). Thus,  the presence of high levels of SIV- 
specific antibody in monkeys not protected against SIV grown 
in monkey cells also argues against the notion that antibodies 
that crossreact between HLA class I antigens and lentivirus 
antigens may play an important role in protection against 
SIV infection (19). It is also unlikely that anti-CD4 antibody 
plays a significant role in the present system since no anti- 
CD4 antibody was detected in the sera of protected monkeys 
by flow cytometry (data not shown), nor is CD4 antigen 
present in the SIV virus preparation (Table 1). Whatever the 
mechanism, the results reported here suggest that antibodies 
against human HLA class I molecule and/or other yet un- 
detected antigen(s) may be useful in immunotherapy against 
HIV infection. 
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